A parallel line of work frames Alzheimers disease as a state of central insulin resistance, sometimes called type 3 diabetes, in which GLP-1R agonism restores neuronal insulin signalling, improves mitochondrial function, and reduces oxidative stress
Multiple cell experiments have shown that IGF-1 LR3 can improve the tight junction structure by upregulating the expression of tight junction proteins such as occludin, ZO-1, claudin-1, etc
T., Borde, M
News & World Report piece, reporter Payton Babb Sy, RN laid out the complexity of human metabolism and biological markers, walking us through the science of why some patients' bodies resist these medications
Whether you are using Compounded Semaglutide or Tirzepatide, the timing of your dose often comes down to your personal schedule and how your body responds to the treatment
The findings are encouraging: Over 70% of patients who discontinued GLP-1 therapy maintained at least a 5% reduction in body weight after 12 months, and more than half maintained a loss of at least 10%